Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme

Abstract Background and Aims Patients with inflammatory bowel disease have increased risk of atherosclerotic cardiovascular [CV] disease [ASCVD]. Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis [UC]. We report major adverse CV events [MACE] in the UC OCTAVE pro...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of Crohn's and colitis 2023-11, Vol.17 (11), p.1761-1770
Hauptverfasser:	Schreiber, Stefan, Rubin, David T, Ng, Siew C, Peyrin-Biroulet, Laurent, Danese, Silvio, Modesto, Irene, Guo, Xiang, Su, Chinyu, Kwok, Kenneth K, Jo, Hyejin, Chen, Yan, Yndestad, Arne, Reinisch, Walter, Dubinsky, Marla C
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!